Piper Sandler lowered the firm’s price target on Arvinas to $55 from $70 and keeps an Overweight rating on the shares. The firm notes Arvinas presented Phase I/II data on bavdegalutamide at ESMO showing PSA50 of 54% in mCRPC men with 878/875 mutations that significantly declined to only 8% in men with L702H mutations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARVN:
- Arvinas upgraded to Outperform from Neutral at Wedbush
- Arvinas presents interim data from Phase 1/2 clinical trial for bavdegalutamide
- Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
- Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
- Cantor biotech/biopharma analysts hold an analyst/industry conference call